# A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct07562022/  
OnCo record `nct07562022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SCTB35 in follicular lymphoma, now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT07562022, led by Sinocelltech, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma. Planned enrolment is 93 participants (estimated). The study started in 2026-06-09 and primary completion is expected in 2028-05. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07562022
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Sponsor: Sinocelltech
- Enrolled: 93

## Sources

- ClinicalTrials.gov NCT07562022: https://clinicaltrials.gov/study/NCT07562022

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [SCTB35](https://onco.cc/drugs/sctb35/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct07562022.json